Evidence map›Paper›PMID 39763831›Full record

ArticlebioRxiv : the preprint server for biology2024

Bispecific antibody targeting of lipid nanoparticles.

Angelo Amabile, Matthew Phelan, Zhixin Yu, Pedro Silva, Adam Marks, Judit Morla-Folch, Moah Sohn, Gurkan Mollaoglu, Chiara Falcomata, Abraham J P Teunissen and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Angelo AmabileIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Matthew PhelanIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Zhixin YuRNA NanoCore - Lipid Nanoparticle Therapeutics Core, ISMMS, New York, NY, USA.
Pedro SilvaIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Adam MarksIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Judit Morla-FolchBiomedical Engineering and Imaging Institute, ISMMS, New Yok, NY, USA.
Moah SohnMarc and Jennifer Lipschultz Precision Immunology Institute, ISMMS, New York, New York, USA.
Gurkan MollaogluIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Chiara FalcomataIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Abraham J P TeunissenBiomedical Engineering and Imaging Institute, ISMMS, New Yok, NY, USA.
Joshua D BrodyMarc and Jennifer Lipschultz Precision Immunology Institute, ISMMS, New York, New York, USA.
Yizhou DongIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Brian D BrownIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.

Funding

Translational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5M
Post-transcriptional regulation of the Dendritic Cell transcriptomeR01AI104848 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2013 to 2017
$2.3M
microRNA-controlled mRNA therapeuticsR01DK138025 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown · 2024 to 2026
$1.7M
NIAID NIH HHS R01 AI104848NIAID NIH HHS T32 AI078892NIDDK NIH HHS R01 DK138025
6 · The paper itself

Abstract

Lipid nanoparticles (LNP) are the most clinically advanced non-viral gene delivery system. While progress has been made for enhancing delivery, cell specific targeting remains a challenge. Targeting moieties such as antibodies can be chemically-conjugated to LNPs however, this approach is complex and has challenges for scaling up. Here, we developed an approach to generate antibody-conjugated LNPs that utilizes a bispecific antibody (bsAb) as the targeting bridge. As a docking site for the bsAb, we generated LNPs with a short epitope, derived from hemagglutinin antigen (HA), embedded in the PEG component of the particle (LNP

Identifiers

PMID39763831
PMCPMC11702604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.